This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Cellceutix Reports Production Of Its Anti-Cancer Drug Kevetrin™ Has Begun

Stocks in this article: CTIX

BEVERLY, Mass., March 14, 2011 /PRNewswire/ -- Cellceutix Corporation (OTCQB: CTIX) is pleased to announce that Kevetrin™, the Company's flagship compound for the potential treatment of cancers not responding to existing drugs (drug-resistant cancers), has begun production for clinical trials. This was confirmed by Formatech Inc.( Andover , MA) which formulates developmental medications for clinical trials.

"We appreciate being given the opportunity to develop and manufacture Kevetrin™, Cellceutix's first clinical candidate," said Indu Javeri, Ph.D., CEO of Formatech. "We have worked closely with Dr. Menon and his team at Cellceutix over the recent months and we look forward to encouraging results from their clinical trials. We understand that Kevetrin has a unique mechanism of action that could dramatically impact the treatment of multiple cancers. In an industry that produces very few truly novel products, it is refreshing to see a new potential chemotherapy compound like Kevetrin™."

Leo Ehrlich, CEO of Cellceutix, commented, "We are thrilled that the production process is underway.  I very much appreciate Dr. Javeri's comments."  Mr. Ehrlich continued, "Our lead compound Kevetrin™ is moving forward, and rapidly garnering attention.  People are now realizing the results and potential of our hard work.  Kevetrin™ has a unique chemical structure; the first in its class of chemistry to be used as an anti-cancer agent. Our preclinical testing results were beyond our best expectations against drug-resistant cancers. Most important of all was the discovery of the p53--Guardian angel--mechanism of action.  These factors are quite important as we move towards clinical trials.  Should we achieve proper efficacy during the planned clinical trials, we hope that the FDA may grant Accelerated Approval or Priority Review for Kevetrin™.  While there are no assurances of success in biotechnology research, at Cellceutix we are enthusiastic about what has been achieved thus far, and believe the best is yet to come."

Accelerated Approval or Priority Review programs by the FDA programs were put into effect approximately twenty years ago specifically for new drugs that provide the best opportunity for a viable therapy in an area of unmet medical need. In these cases, it is to the advantage of all involved to get these compounds to late-stage clinical trials quickly, without sacrificing any safety.  

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,810.06 +91.06 0.51%
S&P 500 2,063.50 +10.75 0.52%
NASDAQ 4,712.97 +11.1030 0.24%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs